Role of PD-L1 in AKI Repair Mechanisms

Acute kidney injury (AKI) frequently occurs in patients receiving anti-PD-L1 immunotherapy. This clinical observation suggests that PD-L1 maintains renal homeostasis. However, the exact mechanism remained unknown until now. A groundbreaking study recently identified a T-cell independent role for PD-L1 in AKI repair. Specifically, the research focuses on how PD-L1 interacts with the BRCA1 protein to safeguard tubular epithelial cells (TECs).

Mechanistic Insights: PD-L1/BRCA1 Synergy

The study found that PD-L1 is primarily expressed in the proximal tubules. Both murine models and human renal biopsies showed a significant upregulation of PD-L1 following injury. When researchers deleted PD-L1 in mouse TECs, renal injury worsened after ischemia-reperfusion. Mechanistically, PD-L1 binds to BRCA1 and increases its expression. Furthermore, this interaction protects the cells against DNA damage. Consequently, the kidney promotes cellular proliferation and suppresses apoptosis to facilitate repair.

Novel Therapeutic Delivery via Extracellular Vesicles

To translate these findings, the team developed a CGA-functionalized extracellular vesicle delivery system. This platform provides targeted delivery of PD-L1 specifically to injured TECs. Additionally, the system effectively restored PD-L1 levels in both PD-L1 knockdown and T-cell knockout mouse models. Thus, PD-L1 supplementation represents a promising therapeutic strategy for treating AKI. Moreover, this pathway operates independently of the canonical immunomodulatory functions associated with T cells.

FAQs

How does PD-L1 facilitate kidney repair?

PD-L1 interacts with BRCA1 to enhance its expression in tubular epithelial cells. This process mitigates DNA damage, which encourages cell survival and promotes the proliferation needed for tissue repair.

Does this role of PD-L1 depend on the immune system?

No, researchers discovered that this specific repair mechanism is T-cell independent. It focuses on the internal stability and DNA repair capacity of the tubular cells themselves rather than immune signaling.

Disclaimer: This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Jiang W et al. T Cell-Independent Role of PD-L1 in Kidney Repair: Mitigation of Tubular DNA Damage via PD-L1/BRCA1 Interaction Following AKI. Adv Sci (Weinh). 2026 Apr 27. doi: 10.1002/advs.75428. PMID: 42043850.


2. Liu J et al. A Novel Renoprotective Strategy: Upregulation of PD-L1 Mitigates Cisplatin-Induced Acute Kidney Injury. Int J Mol Sci. 2021 Dec 10;22(24):13340.


3. Seethapathy H et al. Incidence and Clinical Features of Immune-Related Acute Kidney Injury in Patients Receiving Programmed Cell Death Ligand-1 Inhibitors. Kidney360. 2020 Jan 30;1(1):9-15.